{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:06:11Z","timestamp":1791342371885,"version":"4.3.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["Health-F3-2011-278348"],"award-info":[{"award-number":["Health-F3-2011-278348"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.cmi.2015.06.007","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T06:37:27Z","timestamp":1434523047000},"page":"881-885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Use of old antibiotics now and in the future from a pharmacokinetic\/pharmacodynamic perspective"],"prefix":"10.1016","volume":"21","author":[{"given":"A.E.","family":"Muller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Theuretzbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Mouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2015.06.007_bib1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/archdischild-2014-307297","article-title":"Reducing hospital-acquired infections and improving the rational use of antibiotics in a developing country: An effectiveness study","volume":"100","author":"Murni","year":"2015","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.cmi.2015.06.007_bib2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2710.2011.01293.x","article-title":"Irrational use of antibiotics and role of the pharmacist: An insight from a qualitative study in new delhi, india","volume":"37","author":"Kotwani","year":"2012","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.cmi.2015.06.007_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/jhmas\/jrq003","article-title":"Antibiotics and the social history of the controlled clinical trial, 1950\u20131970","volume":"65","author":"Podolsky","year":"2010","journal-title":"J\u00a0Hist Med Allied Sci"},{"key":"10.1016\/j.cmi.2015.06.007_bib4","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/jac\/dku064","article-title":"Product information for parenteral colistin varies substantially across Europe","volume":"69","author":"Theuretzbacher","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2015.06.007_bib5","series-title":"New EMA guidance on development of antibacterials to help in the fight against multidrug-resistant pathogens","author":"European Medicines Agency","year":"2013"},{"key":"10.1016\/j.cmi.2015.06.007_bib6","series-title":"Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.cmi.2015.06.007_bib7","series-title":"Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections","author":"European Medicines Agency","year":"2013"},{"key":"10.1016\/j.cmi.2015.06.007_bib8","series-title":"Guidance for industry antibacterial drug products: Use of noninferiority trials to support approval","author":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)","year":"2010"},{"issue":"3","key":"10.1016\/j.cmi.2015.06.007_bib9","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","article-title":"The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach","volume":"18","author":"Mouton","year":"2012","journal-title":"Clin Microbiol Infect."},{"issue":"1","key":"10.1016\/j.cmi.2015.06.007_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.cmi.2015.06.007_bib11","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cmi.2015.05.002","article-title":"Optimization of dosing regimens and dosing in special populations","volume":"21","author":"Sime","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2015.06.007_bib12","series-title":"Kucers' the use of antibiotics","author":"Grayson","year":"2010"},{"key":"10.1016\/j.cmi.2015.06.007_bib13","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/jac\/dks468","article-title":"Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia","volume":"68","author":"Muller","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2015.06.007_bib14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0034-1398490","article-title":"Applying pharmacokinetic\/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development","volume":"36","author":"Abdul-Aziz","year":"2015","journal-title":"Semin Resp Crit Care Med"},{"issue":"2","key":"10.1016\/j.cmi.2015.06.007_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1473-3099(14)70850-3","article-title":"Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus","volume":"15","author":"Nation","year":"2015","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.cmi.2015.06.007_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkv147","article-title":"Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials","author":"Huttner","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.cmi.2015.06.007_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0924-8579(02)00028-6","article-title":"Breakpoints: Current practice and future perspectives","volume":"19","author":"Mouton","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2015.06.007_bib18","series-title":"Antimicrobial pharmacodynamics in theory and clinical practice","first-page":"21","article-title":"Applying pharmacodynamics for susceptibility breakpoint selection and susceptibility testing","author":"Mouton","year":"2007"},{"key":"10.1016\/j.cmi.2015.06.007_bib19","series-title":"AIDA\u2014Preserving old antibiotics for the future: assessment of clinical efficacy by a pharmacokinetic\/pharmacodynamic approach to optimize effectiveness and reduce resistance for off-patent antibiotics","author":"European Commission","year":"2011"},{"key":"10.1016\/j.cmi.2015.06.007_bib20","series-title":"NIH funds four clinical trials to fight antimicrobial resistance","author":"National Institutes of Health","year":"2010"},{"issue":"6","key":"10.1016\/j.cmi.2015.06.007_bib21","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/jac\/dkv020","article-title":"Antibiotic research and development: business as usual?","volume":"70","author":"Harbarth","year":"2015","journal-title":"J Antimicrob Chemother."}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15006205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15006205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T09:09:50Z","timestamp":1668762590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X15006205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1198743X15006205"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2015.06.007","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of old antibiotics now and in the future from a pharmacokinetic\/pharmacodynamic perspective","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2015.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}